Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer

References

• Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol.10(10), 981–991 (2009).
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lal P, LaTulippe E et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol.164(1), 217–227 (2004).
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol.27(23), 3742–3748 (2009).
   PubMed Web of Science ®Google Scholar
• Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol.23(32), 8253–8261 (2005).
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1–2 study. Lancet375(9724), 1437–1446 (2010).
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Page ST, Lin DW et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res.67(10), 5033–5041 (2007).
   PubMed Web of Science ®Google Scholar
• Ohlson N, Wikstrom P, Stattin P, Bergh A. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate62(4), 307–315 (2005).
   PubMedGoogle Scholar
• Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res.61(7), 2892–2898 (2001).
   PubMed Web of Science ®Google Scholar
• Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol. Med.17(7–8), 657–664 (2011).
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science324(5928), 787–790 (2009).
   PubMed Web of Science ®Google Scholar
• Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res.68(15), 6407–6415 (2008).
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res.68(11), 4447–4454 (2008).
   PubMed Web of Science ®Google Scholar
• Pelletier G. Expression of steroidogenic enzymes and sex-steroid receptors in human prostate. Best Pract. Res. Clin. Endocrinol. Metab.22(2), 223–228 (2008).
   PubMed Web of Science ®Google Scholar
• Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res.66(5), 2815–2825 (2006).
   PubMed Web of Science ®Google Scholar
• Hofland J, van Weerden WM, Dits NF et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res.70(3), 1256–1264 (2010).
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med.364(21), 1995–2005 (2011).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Agus DB, MacVicar GR et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a Phase I/II, open-label study. J. Clin. Oncol. (Meeting Abstracts)28, 3084 (2010).
   PubMedGoogle Scholar
• Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res.68(13), 5469–5477 (2008).
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Marck BT, Plymate SR et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res.17(18), 5913–5925 (2011).
   PubMed Web of Science ®Google Scholar
• Watson PA, Chen YF, Balbas MD et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl Acad. Sci. USA107(39), 16759–16765 (2010).
   PubMed Web of Science ®Google Scholar